<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pathophysiology</journal-id><journal-id journal-id-type="iso-abbrev">Pathophysiology</journal-id><journal-id journal-id-type="publisher-id">pathophysiology</journal-id><journal-title-group><journal-title>Pathophysiology</journal-title></journal-title-group><issn pub-type="ppub">0928-4680</issn><issn pub-type="epub">1873-149X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407599</article-id><article-id pub-id-type="pmc">PMC12101160</article-id>
<article-id pub-id-type="doi">10.3390/pathophysiology32020019</article-id><article-id pub-id-type="publisher-id">pathophysiology-32-00019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Therapeutic Efficacy of Mesenchymal Stem Cells in Modulating Oxidative Stress in Puromycin-Induced Nephropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iizuka</surname><given-names>Yusuke</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-pathophysiology-32-00019" ref-type="aff">1</xref><xref rid="af2-pathophysiology-32-00019" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7961-9698</contrib-id><name><surname>Sasaki</surname><given-names>Masanori</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-pathophysiology-32-00019" ref-type="aff">2</xref><xref rid="af3-pathophysiology-32-00019" ref-type="aff">3</xref><xref rid="c1-pathophysiology-32-00019" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2833-5078</contrib-id><name><surname>Terada</surname><given-names>Kojiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-pathophysiology-32-00019" ref-type="aff">1</xref><xref rid="af4-pathophysiology-32-00019" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Sakai</surname><given-names>Takuro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-pathophysiology-32-00019" ref-type="aff">1</xref><xref rid="af4-pathophysiology-32-00019" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7138-334X</contrib-id><name><surname>Nagaoka</surname><given-names>Yoshinobu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af1-pathophysiology-32-00019" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9829-4833</contrib-id><name><surname>Fukumura</surname><given-names>Shinobu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-pathophysiology-32-00019" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3780-7719</contrib-id><name><surname>Kocsis</surname><given-names>Jeffery D.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-pathophysiology-32-00019" ref-type="aff">3</xref><xref rid="af5-pathophysiology-32-00019" ref-type="aff">5</xref><xref rid="af6-pathophysiology-32-00019" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7226-3000</contrib-id><name><surname>Tsugawa</surname><given-names>Takeshi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-pathophysiology-32-00019" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Honmou</surname><given-names>Osamu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-pathophysiology-32-00019" ref-type="aff">2</xref><xref rid="af3-pathophysiology-32-00019" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Alexander</surname><given-names>Jonathan Steven</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pathophysiology-32-00019"><label>1</label>Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo 060-8556, Hokkaido, Japan; <email>i.yusuke@sapmed.ac.jp</email> (Y.I.); <email>terada.kojiro@sapmed.ac.jp</email> (K.T.); <email>yonagao@sapmed.ac.jp</email> (Y.N.); <email>tsugawat@sapmed.ac.jp</email> (T.T.)</aff><aff id="af2-pathophysiology-32-00019"><label>2</label>Department of Neural Regenerative Medicine, Institute of Regenerative Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Hokkaido, Japan</aff><aff id="af3-pathophysiology-32-00019"><label>3</label>Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA</aff><aff id="af4-pathophysiology-32-00019"><label>4</label>Department of Perinatal Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Hokkaido, Japan</aff><aff id="af5-pathophysiology-32-00019"><label>5</label>Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA</aff><aff id="af6-pathophysiology-32-00019"><label>6</label>Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare System, West Haven, CT 06510, USA</aff><author-notes><corresp id="c1-pathophysiology-32-00019"><label>*</label>Correspondence: <email>msasaki@sapmed.ac.jp</email>; Tel.: +81-11-611-2111 (ext. 25070); Fax: +81-11-616-3112</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>32</volume><issue>2</issue><elocation-id>19</elocation-id><history><date date-type="received"><day>11</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold><italic toggle="yes">Background:</italic></bold> Podocytes are essential for kidney function, and their dysfunction can result in nephrotic syndrome, such as minimal change disease (MCD). Oxidative stress contributes to podocyte damage. We investigated the therapeutic potential of intravenously infused mesenchymal stem cells (MSCs) in a puromycin aminonucleoside (PAN)-induced rodent MCD model, focusing on oxidative stress modulation. <bold><italic toggle="yes">Methods:</italic></bold> Sprague-Dawley rats were divided into three groups: intact, PAN-Vehicle, and PAN-MSC. MCD was induced through subcutaneous PAN injection. MSCs were infused intravenously in the PAN-MSC group on day 7. Urinary albumin, serum albumin, and creatinine levels were assessed. Histological analysis of the renal cortex was performed. Podocyte protein (NPHS1, NPHS2, and PODXL) and antioxidant enzyme (SOD1, SOD2, and GPX1) levels were measured using quantitative real-time reverse-transcription PCR (qRT-PCR). <bold><italic toggle="yes">Results:</italic></bold> MSC infusion significantly reduced proteinuria and restored podocyte structure in the PAN-MSC group. Electron microscopy revealed that infused MSCs could inhibit the fusion of the foot process induced by PAN injection. qRT-PCR showed that intravenous infusion of MSCs rescued the inhibition of GPX1 expression. GFP-labeled MSCs accumulated at the podocyte injury sites. <bold><italic toggle="yes">Conclusion:</italic></bold> Systemic MSC infusion mitigates PAN-induced MCD by reducing proteinuria, preserving podocyte structure, and modulating oxidative stress via the GPX1 pathway, offering a potential therapeutic approach for nephrotic syndrome.</p></abstract><kwd-group><kwd>intravenous</kwd><kwd>mesenchymal stem cell</kwd><kwd>minimal change disease</kwd><kwd>puromycin aminonucleoside</kwd></kwd-group><funding-group><award-group><funding-source>Sapporo Medical University</funding-source></award-group><award-group><funding-source>JSPS KAKENHI</funding-source><award-id>23K08095</award-id></award-group><award-group><funding-source>RR&#x00026;D Service of the US Department of Veterans Affairs</funding-source><award-id>B7335R</award-id><award-id>B9260L</award-id></award-group><funding-statement>This work was supported in part by the funding for education and research at Sapporo Medical University, the JSPS KAKENHI grant (grant number 23K08095), and the RR&#x00026;D Service of the US Department of Veterans Affairs (grants B7335R and B9260L).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pathophysiology-32-00019"><title>1. Introduction</title><p>Podocytes are highly specialized, terminally differentiated epithelial cells with a critical role in renal function, and are characterized by a complex cellular architecture [<xref rid="B1-pathophysiology-32-00019" ref-type="bibr">1</xref>,<xref rid="B2-pathophysiology-32-00019" ref-type="bibr">2</xref>]. Podocyte dysfunction leads to nephrotic syndrome, including minimal change disease (MCD) [<xref rid="B3-pathophysiology-32-00019" ref-type="bibr">3</xref>,<xref rid="B4-pathophysiology-32-00019" ref-type="bibr">4</xref>]. The loss of podocyte foot processes correlates closely with the development of protein leakage across the glomerular filtration barrier, resulting in proteinuria [<xref rid="B5-pathophysiology-32-00019" ref-type="bibr">5</xref>,<xref rid="B6-pathophysiology-32-00019" ref-type="bibr">6</xref>]. While the molecular mechanisms underlying alterations in podocyte structure and function in nephrotic syndrome remain poorly understood, oxidative injury has been proposed as a possible indirect contributor to those changes [<xref rid="B7-pathophysiology-32-00019" ref-type="bibr">7</xref>,<xref rid="B8-pathophysiology-32-00019" ref-type="bibr">8</xref>]. Oxidative stress is a potential cause of podocyte damage and subsequently affects the integrity of the glomerular barrier [<xref rid="B9-pathophysiology-32-00019" ref-type="bibr">9</xref>,<xref rid="B10-pathophysiology-32-00019" ref-type="bibr">10</xref>].</p><p>Oxidative stress and reduced activity of antioxidant enzymes contribute to the development of renal diseases [<xref rid="B11-pathophysiology-32-00019" ref-type="bibr">11</xref>,<xref rid="B12-pathophysiology-32-00019" ref-type="bibr">12</xref>]. Podocyte injury induced by puromycin aminonucleoside (PAN) results in the induction of podocyte antioxidant enzyme activities [<xref rid="B7-pathophysiology-32-00019" ref-type="bibr">7</xref>,<xref rid="B13-pathophysiology-32-00019" ref-type="bibr">13</xref>]. Therefore, PAN injection in rodents is a well-described nephrosis model system for the induction of experimental nephrotic syndrome, similar to human MCD [<xref rid="B14-pathophysiology-32-00019" ref-type="bibr">14</xref>,<xref rid="B15-pathophysiology-32-00019" ref-type="bibr">15</xref>,<xref rid="B16-pathophysiology-32-00019" ref-type="bibr">16</xref>]. </p><p>Cellular therapy with mesenchymal stem cells (MSCs) for MCD using the PAN injury model has been reported to have therapeutic efficacy via anti-inflammatory/immunomodulatory effects following direct injection of MSCs [<xref rid="B14-pathophysiology-32-00019" ref-type="bibr">14</xref>]. However, the potential role of intravenously delivered MSCs in alleviating oxidative stress in this model has not been explored.</p><p>In this study, we investigated whether intravenously infused MSCs exert a therapeutic effect on a rat MCD model caused by PAN-induced podocyte injury by an antioxidant mechanism. We performed urinalysis, blood tests, histological analysis (including light and electron microscopy), and quantitative real-time reverse-transcription PCR (qRT-PCR) on the renal cortex.</p></sec><sec id="sec2-pathophysiology-32-00019"><title>2. Materials and Methods</title><sec id="sec2dot1-pathophysiology-32-00019"><title>2.1. Preparation of MSCs from the Rat Bone Marrow</title><p>The MSC culture preparation was based on our previous studies [<xref rid="B17-pathophysiology-32-00019" ref-type="bibr">17</xref>]. Briefly, bone marrow obtained from femoral bones of five wild-type Sprague-Dawley (Slc: SD, Japan SLC, Shizuoka, Japan) or two green fluorescent protein (GFP)-expressing (W-Tg [CAG-GFP]184Ys, # NBRP Rat No: 0273, National BioResource Project&#x02014;Rat, Kyoto University, Kyoto, Japan) rats (6&#x02013;8 weeks old) was diluted with Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; Millipore Sigma, St. Louis, MO, USA) to a volume of 15 mL and supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific Inc., Waltham, MA, USA), 2 mM L-glutamine (Millipore Sigma), 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Thermo Fisher Scientific Inc.), and was incubated for 7 days at 37 &#x000b0;C in a humidified atmosphere containing 5% CO<sub>2</sub>. When the cultures almost reached confluence, the adherent cells were detached with a trypsin-ethylenediaminetetraacetic acid solution (Millipore Sigma) and subcultured at 1 &#x000d7; 10<sup>4</sup> cells/mL of medium. After three passages, the MSCs were used. A previous phenotypic analysis of surface antigens revealed clusters of differentiation (CD) 45<sup>&#x02212;</sup>, CD73<sup>+</sup>, CD90<sup>+</sup>, and CD106<sup>-</sup> on MSCs [<xref rid="B18-pathophysiology-32-00019" ref-type="bibr">18</xref>], and MSCs differentiate into mesenchymal derivatives, including osteocytes, adipocytes, and chondrocytes [<xref rid="B19-pathophysiology-32-00019" ref-type="bibr">19</xref>].</p></sec><sec id="sec2dot2-pathophysiology-32-00019"><title>2.2. Animal Model</title><p>Male SD rats weighing 180&#x02013;210 g (6-week-old) were used. The MCD was induced by PAN (#15509, Cayman Chemical, Ann Arbor, MI, USA) modified from Frenk et al. [<xref rid="B20-pathophysiology-32-00019" ref-type="bibr">20</xref>] and Hosoyamada et al. [<xref rid="B21-pathophysiology-32-00019" ref-type="bibr">21</xref>]. PAN was diluted to 20 mg/mL with saline and injected subcutaneously at 200 mg/kg body weight. All rats were maintained in a temperature-controlled environment with a 12 h light/dark cycle and were given a standard diet and water ad libitum during the study period.</p></sec><sec id="sec2dot3-pathophysiology-32-00019"><title>2.3. Experimental Protocol</title><p>The experimental protocol is illustrated in <xref rid="pathophysiology-32-00019-f001" ref-type="fig">Figure 1</xref>. The SD rats were divided into intact (n = 6), PAN-Vehicle (n = 6), and PAN-MSC (n = 6) groups. As described above, PAN was injected to induce the MCD model on day 0. For the intact group, rats were administered normal saline (NS) subcutaneously (2.0 mL/100 g body weight) on day 0. Urine samples were collected before PAN or NS injection, and at 5, 10, and 15 days after PAN or NS injection using a metabolic cage (3700M071, Tecniplast Japan Co., Ltd., Tokyo, Japan). All PAN-treated rats were confirmed to have proteinuria on day 5. On day 7, they were randomized and anesthetized with an intraperitoneal (IP) injection of ketamine and xylazine (90/4 mg/kg) and received a single intravenous infusion of MSCs at 1.0 &#x000d7; 10<sup>6</sup> in 1.0 mL of total volume (fresh DMEM) or vehicle (1.0 mL of fresh DMEM alone) via the left femoral vein. For the intact group, rats received vehicle (1.0 mL of fresh DMEM alone) via the left femoral vein on day 7. All rats were injected subcutaneously daily with cyclosporine A (5 mg/kg), starting one day before MSC, or vehicle infusion until 15 days after injection of PAN or NS.</p></sec><sec id="sec2dot4-pathophysiology-32-00019"><title>2.4. Urine Protein</title><p>To analyze 24-h urinary albumin excretion, rats were maintained in metabolic cages for 24 h every 5 days until day 15 (3700M071, Tecniplast Japan Co., Ltd.). Albuminuria was measured using enzyme-linked immunosorbent assay (n = 6/group) (LBIS&#x02122; Rat Albumin ELISA Kit, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) [<xref rid="B22-pathophysiology-32-00019" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot5-pathophysiology-32-00019"><title>2.5. Blood and Tissue Sample Collection</title><p>On day 15, rats (n = 6/group) were deeply anesthetized with an IP injection of ketamine (180 mg/kg) and xylazine (20 mg/kg) for euthanasia. Blood samples (2 mL) were collected from the heart. After being perfused with phosphate-buffered saline (PBS), the fresh right renal cortex was dissected for electron microscopy and RT-PCR. Then, the rats were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer. The left renal cortex was dissected and post-fixed in 4% paraformaldehyde overnight. The fixed left renal cortex was embedded in paraffin for periodic acid-Schiff (PAS) staining.</p></sec><sec id="sec2dot6-pathophysiology-32-00019"><title>2.6. Blood Analysis</title><p>Blood samples were centrifuged at 3000 rpm for 10 min to extract the serum and then stored at &#x02212;80 &#x000b0;C until use. The collected serum was analyzed for serum albumin (sAlb) and serum creatinine (sCr) using DRI-CHEM NX600 (Fujifilm, Tokyo, Japan) [<xref rid="B23-pathophysiology-32-00019" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot7-pathophysiology-32-00019"><title>2.7. PAS Staining</title><p>The 4-&#x003bc;m-thick sections of the paraffin-embedded left kidney were cut (RM2235, Leica, Heidelberg, Germany) and stained with PAS reagent (#40922, Muto Pure Chemicals Co., Ltd., Tokyo, Japan). PAS-stained sections were examined and photographed under a light microscope (BZ-X700; Keyence Corporation, Osaka, Japan).</p></sec><sec id="sec2dot8-pathophysiology-32-00019"><title>2.8. Electron Microscopic Analysis</title><p>Dissected fresh kidneys were subjected to primary fixation with 2.5% glutaraldehyde in sodium phosphate buffer. The sections were post-fixed with 1% osmium tetroxide for 4 h, dehydrated in graded ethanol, and embedded in Epox-812 (TAAB Laboratories Equipment Ltd., Berks, UK). Ultrathin sections (70 nm) were cut using an ultramicrotome (MT-X; RMT Boeckeler Instruments, Inc., Tucson, AZ, USA) and stained with uranyl acetate and lead citrate. Ultrathin sections were examined using an electron microscope (15,000&#x000d7; magnification, JEM-1400, JEOL Ltd., Tokyo, Japan) operating at 80 kV. Fifty fields per animal were examined to determine the average foot process width. In each image, the curved total length of the glomerular basement membrane (BML) was measured using ImageJ (J.1.53K; Java 1.8.0_172 (64-bit), National Institutes of Health, Bethesda, MD, USA) by counting the number of slit diaphragms (Slits). The average foot process width was calculated using the formula Wp = &#x003c0;/4 &#x000d7; &#x003a3;BML/Slits [<xref rid="B14-pathophysiology-32-00019" ref-type="bibr">14</xref>,<xref rid="B24-pathophysiology-32-00019" ref-type="bibr">24</xref>].</p></sec><sec id="sec2dot9-pathophysiology-32-00019"><title>2.9. RT-PCR</title><p>Quantitative RT-PCR was performed as previously described [<xref rid="B25-pathophysiology-32-00019" ref-type="bibr">25</xref>]. Renal cortices from each group were collected using a dissection microscope. Total RNA was extracted using an RNeasy Plus Mini Kit (#74134, Qiagen, Valencia, CA, USA) according to the manufacturer&#x02019;s instructions. RNA (5 &#x003bc;g) was reverse-transcribed into cDNA using Superscript IV VILO Master Mix (Qiagen). Real-time PCR for each sample was performed in triplicate with TaqMan Universal Master Mix II with UNG (Thermo Fisher Scientific Inc.). The following sets of specific primers and TaqMan probes were purchased from Thermo Fisher Scientific Inc.: glyceraldehyde-3-phosphate dehydrogenase (<italic toggle="yes">GAPDH</italic>) (TaqMan rodent GAPDH control reagents, Rn01775763_g1) as endogenous control, and nephrin (<italic toggle="yes">NPHS1</italic>; Rn00575235_m1) [<xref rid="B26-pathophysiology-32-00019" ref-type="bibr">26</xref>], podocin (<italic toggle="yes">NPHS2</italic>, Rn00709834_m1) [<xref rid="B26-pathophysiology-32-00019" ref-type="bibr">26</xref>], podocalyxin (<italic toggle="yes">PODXL</italic>; Rn00593804_m1) [<xref rid="B26-pathophysiology-32-00019" ref-type="bibr">26</xref>], superoxide dismutase type 1 (<italic toggle="yes">SOD1</italic>; Rn01477288_m1), superoxide dismutase type 2 (<italic toggle="yes">SOD2</italic>; Rn00566942_g1), and glutathione peroxidase 1 (<italic toggle="yes">GPX1</italic>; Rn00577994_g1) [<xref rid="B27-pathophysiology-32-00019" ref-type="bibr">27</xref>] as target genes. The qRT-PCR analysis was performed in triplicate using PRISM7500 with 7500 software v2.3 (Thermo Fisher Scientific Inc.). Thermal cycling was conducted at 50 &#x000b0;C for 2 min and 95 &#x000b0;C for 10 min, followed by 40 cycles of 95 &#x000b0;C for 15 s and 60 &#x000b0;C for 1 min. The delta cycle threshold (Ct) (&#x00394;CT) was calculated against the endogenous control (<italic toggle="yes">GAPDH</italic>), and the delta-delta Ct (&#x00394;&#x00394;CT) was calculated against the &#x00394;CT of the control. Fold change was also calculated using the comparative Ct method [<xref rid="B28-pathophysiology-32-00019" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot10-pathophysiology-32-00019"><title>2.10. Detection of GFP-Expressing MSCs In Vivo</title><p>Six additional MCD rats were induced by the injection of PAN. The MCD rats were used to detect the infused MSCs in vivo. The MCD rats were infused with GFP-MSCs (n = 3) and non-GFP-MSCs (n = 3). GFP-MSCs were derived from GFP-expressing rats, and non-GFP-MSCs were derived from wild-type SD rats. One day after the injection of GFP-MSCs or non-GFP-MSCs, the MCD rats were deeply anesthetized with ketamine and xylazine (50/10 mg/kg, IP) and perfused with saline and 0.1 M phosphate buffer following 4% paraformaldehyde. The kidney was dissected, post-fixed in 4% paraformaldehyde overnight, cryoprotected in 30% sucrose/phosphate-buffered saline at 4 &#x000b0;C, embedded in OCT compound (Sakura Finetek USA, Inc., Torrance, CA, USA), and finally stored at &#x02212;80 &#x000b0;C until use. Midcoronal sections (40 &#x000b5;m thickness) were prepared using a cryostat (Sakura Seiki Co., Ltd., Nagano, Japan) and mounted on glass slides. The sections were washed three times in PBS and 0.1% Tween 20, blocked in 10% normal goat serum and 0.3% Triton X-100 in PBS at room temperature for 60 min. The cryosections were processed for immunolabeling using a chicken anti-GFP antibody (1:500; ab13970, Abcam, Cambridge, UK). After washing four times in PBS-T, the sections were incubated with secondary antibodies using AF 488-conjugated goat anti-chicken IgY for GFP (1:1000; ab150169, Abcam). Furthermore, they were counterstained with 4,6-diamidino-2-phenylindole and covered with VECTORSHIELD (Vector Laboratories, Burlingame, CA, USA). The frozen sections were examined under a fluorescence microscope (BZ-X700; Keyence Corporation, Osaka, Japan).</p></sec><sec id="sec2dot11-pathophysiology-32-00019"><title>2.11. Statistical Analysis</title><p>All statistical analyses were performed using JMP Pro 16 for Windows (SAS institute, Cary, NC, USA). Differences among groups were assessed using the Kruskal&#x02013;Wallis test. A <italic toggle="yes">p</italic>-value of &#x0003c;0.05 was considered statistically significant. All data are presented as the mean &#x000b1; standard error of the mean (SEM).</p></sec></sec><sec sec-type="results" id="sec3-pathophysiology-32-00019"><title>3. Results</title><sec id="sec3dot1-pathophysiology-32-00019"><title>3.1. Urine Albumin and Kidney Function</title><p>Renal function was analyzed using a urinary albumin test (<xref rid="pathophysiology-32-00019-f002" ref-type="fig">Figure 2</xref>a), sAlb (<xref rid="pathophysiology-32-00019-f002" ref-type="fig">Figure 2</xref>b), and sCr (<xref rid="pathophysiology-32-00019-f002" ref-type="fig">Figure 2</xref>c) levels. The PAN-Vehicle group induced severe albuminuria as early as day 5, which peaked on days 10&#x02013;15. Intravenous infusion of MSCs (PAN-MSC group) significantly reduced albuminuria on days 10&#x02013;15 compared with the PAN-Vehicle group. No urinary albumin was detected in the intact group. sAlb in the PAN-Vehicle group was significantly lower than that in the intact group; however, it was significantly greater in the PAN-MSC group than in the PAN-Vehicle group. While sCr in the PAN-Vehicle group was significantly higher than that in the intact group, it was lower in the PAN-MSC group than in the PAN-Vehicle group. These results indicated that infused MSCs reduced the deterioration of renal function.</p></sec><sec id="sec3dot2-pathophysiology-32-00019"><title>3.2. Light Microscopy with PAS Staining</title><p>Histological findings of the glomeruli revealed no observable pathological features, such as focal segmental glomerulosclerosis, mesangial expansion, crescent formation, or fibrosis, in all groups using light microscopy with PAS staining. There were no differences among the intact (<xref rid="pathophysiology-32-00019-f003" ref-type="fig">Figure 3</xref>a), PAN-Vehicle (<xref rid="pathophysiology-32-00019-f003" ref-type="fig">Figure 3</xref>b), and PAN-MSC (<xref rid="pathophysiology-32-00019-f003" ref-type="fig">Figure 3</xref>c) groups.</p></sec><sec id="sec3dot3-pathophysiology-32-00019"><title>3.3. Electron Microscopy</title><p>Electron microscopy showed normal podocyte morphology in the intact group (<xref rid="pathophysiology-32-00019-f004" ref-type="fig">Figure 4</xref>a). However, podocytes in the PAN-Vehicle group (<xref rid="pathophysiology-32-00019-f004" ref-type="fig">Figure 4</xref>b) showed extensive effacement of the foot processes without detachment, which is a characteristic of MCD. The conventional characteristic of podocyte effacement is widening of the foot processes and a decrease in the length of the slit diaphragm per glomerular basement membrane area [<xref rid="B29-pathophysiology-32-00019" ref-type="bibr">29</xref>]. The PAN-MSC group (<xref rid="pathophysiology-32-00019-f004" ref-type="fig">Figure 4</xref>c) showed less effacement of the foot processes. The quantification of the podocyte foot width on day 15 (<xref rid="pathophysiology-32-00019-f004" ref-type="fig">Figure 4</xref>d) showed that the podocyte foot width in the PAN-Vehicle group was wider than that in the intact group. The podocyte foot width in the PAN-MSC group was shorter than that in the PAN-Vehicle group. There were no differences between the intact and PAN-MSC groups. These results indicate that infused MSCs may inhibit the foot process fusion induced by PAN injection.</p></sec><sec id="sec3dot4-pathophysiology-32-00019"><title>3.4. Expression of Podocyte-Associated Proteins</title><p>To investigate the podocyte-associated proteins in the current study, we performed qRT-PCR to assess the mRNA expression levels of <italic toggle="yes">NPHS1</italic> (<xref rid="pathophysiology-32-00019-f005" ref-type="fig">Figure 5</xref>a), <italic toggle="yes">NPHS2</italic> (<xref rid="pathophysiology-32-00019-f005" ref-type="fig">Figure 5</xref>b), and <italic toggle="yes">PODXL</italic> (<xref rid="pathophysiology-32-00019-f005" ref-type="fig">Figure 5</xref>c). The mRNA expression of these three genes was downregulated in the PAN-Vehicle group compared with the intact group. Meanwhile, the mRNA expression of three genes was upregulated in the PAN-MSC group compared with the PAN-Vehicle group. The mRNA expression of <italic toggle="yes">NPHS1</italic> and <italic toggle="yes">PODXL</italic> was higher in the intact group than in the PAN-MSC group. There were no differences in <italic toggle="yes">NPHS2</italic> between the intact and PAN-MSC groups. These results suggest that infused MSCs may contribute to restoring podocyte damage induced by the PAN injection.</p></sec><sec id="sec3dot5-pathophysiology-32-00019"><title>3.5. Antioxidant Enzyme Activity</title><p>To examine the activity of antioxidant enzymes in this study, the mRNA expression of <italic toggle="yes">SOD1</italic> (<xref rid="pathophysiology-32-00019-f005" ref-type="fig">Figure 5</xref>d), <italic toggle="yes">SOD2</italic> (<xref rid="pathophysiology-32-00019-f005" ref-type="fig">Figure 5</xref>e), and <italic toggle="yes">GPX1</italic> (<xref rid="pathophysiology-32-00019-f005" ref-type="fig">Figure 5</xref>f) was quantified. There were no differences between the three groups in the expression of <italic toggle="yes">SOD1</italic> and <italic toggle="yes">SOD2</italic>. However, the mRNA expression of <italic toggle="yes">GPX1</italic> was downregulated in the PAN-Vehicle group compared with the intact group. The expression levels in the PAN-MSC group were not downregulated compared with the intact group, and the expression levels in the PAN-MSC group were higher than those in the PAN-Vehicle group.</p></sec><sec id="sec3dot6-pathophysiology-32-00019"><title>3.6. Detection of GFP-MSCs</title><p>GFP signals were detected in the glomerulus by observing green fluorescence (<xref rid="pathophysiology-32-00019-f006" ref-type="fig">Figure 6</xref>a), indicating that GFP-MSCs may accumulate at the podocyte injury site. To rule out the possibility of autofluorescence at the GFP detection wavelength, we examined tissue sections from PAN-treated rats infused with non-GFP-MSCs derived from wild-type SD rats. No GFP<sup>+</sup> cells were observed in these control rats (<xref rid="pathophysiology-32-00019-f006" ref-type="fig">Figure 6</xref>b).</p></sec></sec><sec sec-type="discussion" id="sec4-pathophysiology-32-00019"><title>4. Discussion</title><p>In this study, we aimed to elucidate the therapeutic mechanism of MSCs in a rodent model of MCD induced by PAN injection through subcutaneous administration of PA (200 mg/kg body weight), mimicking the clinical and pathological features of human nephrotic syndrome. PAN is a classic and well-established nephrotoxic agent [<xref rid="B30-pathophysiology-32-00019" ref-type="bibr">30</xref>]. The PAN-injected rats displayed deteriorated renal function and extensive effacement of the foot processes of podocytes, indicating the establishment of MCD, which was consistent with the findings of previous studies [<xref rid="B14-pathophysiology-32-00019" ref-type="bibr">14</xref>]. Intravenous infusion of MSCs provided therapeutic efficacy, as evidenced by improvement in renal function and podocyte structure. Gene expression analysis revealed that the podocyte-associated proteins (<italic toggle="yes">NPHS1</italic>, <italic toggle="yes">NPHS2</italic>, and <italic toggle="yes">PODXL</italic>) were downregulated following PAN injection, and their expression was maintained in the PAN-MSC group similar to the intact group, indicating a protective effect of MSCs at the molecular level.</p><p>To elucidate the role of oxidative stress in this model system, we examined the mRNA expression of key antioxidant enzymes. The mRNA expression levels of SOD1 and SOD2 did not show significant differences among the three groups. It is possible that PAN-induced nephrotoxicity in the current study was not strong enough to change the mRNA expression of SOD1 and SOD2 [<xref rid="B31-pathophysiology-32-00019" ref-type="bibr">31</xref>]. However, the mRNA expression level of GPX1 was downregulated in the PAN-Vehicle group compared with the intact group [<xref rid="B32-pathophysiology-32-00019" ref-type="bibr">32</xref>]. Taken together, these findings indicate that while the expression levels of SOD1 and SOD2 remained unchanged, only the expression of GPX1 was affected. This unique pattern of antioxidant enzyme expression observed in this study could contribute to identifying the possible action site of MSCs. The alteration in GPX1 alone suggests that infused MSCs may potentially influence GPX1 activity in podocytes. Further studies are needed to fully elucidate the therapeutic mechanisms after infusing MSCs in PAN-induced podocyte injury related to oxidative stress.</p><p>The rat model of MCD induced by PAN administration was established with stable expression of SOD and downregulation of GPX1 activity. GPX1 is an intracellular antioxidant enzyme that uses reduced glutathione to convert H<sub>2</sub>O<sub>2</sub> to water to limit its harmful effects [<xref rid="B33-pathophysiology-32-00019" ref-type="bibr">33</xref>]. Downregulated expression of GPX1 induced podocyte injury due to excessive H<sub>2</sub>O<sub>2</sub> accumulation. Accumulation of H<sub>2</sub>O<sub>2</sub> exerts podocyte injury [<xref rid="B33-pathophysiology-32-00019" ref-type="bibr">33</xref>]. Infused MSCs in this study inhibited the downregulation of mRNA expression of GPX1 in the PAN-MSC group, which may reduce excessive H<sub>2</sub>O<sub>2</sub>. This might reduce the damage to podocytes in the PAN-MSC group. We observed improved renal function with restored GPX1 following intravenous infusion of MSCs in this model. Thus, the beneficial effects on kidney function through the protection of GPX1 expression by intravenous infusion of MSCs might be a novel finding in the current study.</p><p>Ornellas et al. (2019) employed a severe form of the podocyte injury model induced by two doses of PAN with unilateral nephrectomy [<xref rid="B14-pathophysiology-32-00019" ref-type="bibr">14</xref>]. Direct injection of MSCs under the kidney capsule in the model resulted in renal protection. Injected MSCs induced the downregulation of proinflammatory Th1 cytokines with a shift to an increase in regulatory Th2 cytokines associated with increased vascular endothelial growth factor expression in the kidney, suggesting immunomodulatory effects by injected MSCs [<xref rid="B14-pathophysiology-32-00019" ref-type="bibr">14</xref>]. Since oxidative stress has been identified as a key contributing factor to inducing PAN-mediated podocyte injury [<xref rid="B34-pathophysiology-32-00019" ref-type="bibr">34</xref>,<xref rid="B35-pathophysiology-32-00019" ref-type="bibr">35</xref>], we investigated whether infused MSCs are related to the modulation of oxidative stress. We found that infused MSCs play an important role in improving renal function in a PAN-induced podocyte injury via the GPX1 mechanism.</p><p>This study provides evidence that intravenously infused MSCs can mitigate the effects of PAN-induced MCD in a rodent model by modulating oxidative stress and improving renal function. Accumulated GFP<sup>+</sup>-MSCs were found in the glomeruli, with few detectable fluorescence signals in the other renal areas. This suggests a tropism of MSCs toward the injured area. Indeed, we previously reported the accumulation of MSCs in injury areas in various disease models [<xref rid="B17-pathophysiology-32-00019" ref-type="bibr">17</xref>,<xref rid="B25-pathophysiology-32-00019" ref-type="bibr">25</xref>]. The preservation of GPX1 expression, coupled with consistent levels of SOD1 and SOD2, suggests an enzyme-specific antioxidant response that is effectively facilitated by intravenous infusion of MSCs. These findings highlight the potential of infused MSCs as a promising therapeutic approach for nephrotic syndrome and provide a novel mechanism by which MSCs exert their protective effects via oxidative stress pathways. Future studies should elucidate the detailed molecular interactions between MSCs and podocytes, especially those involved in oxidative stress pathways, and their interplay with other relevant signaling mechanisms, including anti-inflammatory pathways. The insights gained from this study could pave the way for the development of advanced MSC-based therapies that could significantly improve outcomes for patients with nephrotic syndrome and other related kidney diseases. Finally, although prednisone was not used in the current study, it could be incorporated into future studies to explore potential additive or synergistic effects.</p></sec><sec sec-type="conclusions" id="sec5-pathophysiology-32-00019"><title>5. Conclusions</title><p>This study demonstrates that intravenously infused MSCs significantly improve renal function and podocyte structure in a rodent model of PAN-induced MCD. Infused MSCs reduced proteinuria, preserved podocyte foot processes, and maintained the expression of key podocyte-associated proteins. The therapeutic effects are likely due to the modulation of oxidative stress, as evidenced by the protection of GPX1.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are thankful to the National BioResource Project&#x02014;Rat (<uri xlink:href="http://www.anim.med.kyoto-u.ac.jp/NBR/">http://www.anim.med.kyoto-u.ac.jp/NBR/</uri>) (accessed on 29 April 2025) for providing this rat strain (W-Tg (CAG-GFP) 184Ys).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, Y.I., M.S. and O.H.; methodology, Y.I. and M.S.; validation, K.T. and T.S.; formal analysis, Y.I.; investigation, Y.I.; resources, O.H.; data curation, Y.I. and M.S.; writing&#x02014;original draft preparation, Y.I., M.S., J.D.K. and O.H.; writing&#x02014;review and editing, Y.I., M.S., J.D.K. and O.H.; visualization, Y.I.; supervision, T.T. and O.H.; project administration, S.F., Y.N., T.T. and O.H.; funding acquisition, Y.N. and O.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All experiments were performed in accordance with the institutional guidelines of Sapporo Medical University. The use of animals in this study was approved by the Animal Care and Use Committee of Sapporo Medical University. The study was carried out in compliance with the ARRIVE guidelines.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pathophysiology-32-00019"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Jin</surname><given-names>Q.</given-names></name>
<name><surname>Ren</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Mao</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Zhan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Potential therapeutic effects of natural compounds targeting autophagy to alleviate podocyte injury in glomerular diseases</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>155</volume><elocation-id>113670</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113670</pub-id><pub-id pub-id-type="pmid">36116248</pub-id>
</element-citation></ref><ref id="B2-pathophysiology-32-00019"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000f6;ing</surname><given-names>K.</given-names></name>
<name><surname>Michgehl</surname><given-names>U.</given-names></name>
<name><surname>Mertens</surname><given-names>N.D.</given-names></name>
<name><surname>Picciotto</surname><given-names>C.</given-names></name>
<name><surname>Maywald</surname><given-names>M.L.</given-names></name>
<name><surname>Goretzko</surname><given-names>J.</given-names></name>
<name><surname>Waimann</surname><given-names>S.</given-names></name>
<name><surname>Gilhaus</surname><given-names>K.</given-names></name>
<name><surname>Rogg</surname><given-names>M.</given-names></name>
<name><surname>Schell</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Disruption of the Rab7-Dependent Final Common Pathway of Endosomal and Autophagic Processing Results in a Severe Podocytopathy</article-title><source>J. Am. Soc. Nephrol.</source><year>2023</year><volume>34</volume><fpage>1191</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1681/ASN.0000000000000126</pub-id><pub-id pub-id-type="pmid">37022133</pub-id>
</element-citation></ref><ref id="B3-pathophysiology-32-00019"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kopp</surname><given-names>J.B.</given-names></name>
<name><surname>Anders</surname><given-names>H.-J.</given-names></name>
<name><surname>Susztak</surname><given-names>K.</given-names></name>
<name><surname>Podest&#x000e0;</surname><given-names>M.A.</given-names></name>
<name><surname>Remuzzi</surname><given-names>G.</given-names></name>
<name><surname>Hildebrandt</surname><given-names>F.</given-names></name>
<name><surname>Romagnani</surname><given-names>P.</given-names></name>
</person-group><article-title>Podocytopathies</article-title><source>Nat. Rev. Dis. Primers</source><year>2020</year><volume>6</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-0196-7</pub-id><pub-id pub-id-type="pmid">32792490</pub-id>
</element-citation></ref><ref id="B4-pathophysiology-32-00019"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eddy</surname><given-names>A.A.</given-names></name>
<name><surname>Symons</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Nephrotic syndrome in childhood</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>629</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14184-0</pub-id><pub-id pub-id-type="pmid">12944064</pub-id>
</element-citation></ref><ref id="B5-pathophysiology-32-00019"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Purohit</surname><given-names>S.</given-names></name>
<name><surname>Piani</surname><given-names>F.</given-names></name>
<name><surname>Ordo&#x000f1;ez</surname><given-names>F.A.</given-names></name>
<name><surname>de Lucas-Collantes</surname><given-names>C.</given-names></name>
<name><surname>Bauer</surname><given-names>C.</given-names></name>
<name><surname>Cara-Fuentes</surname><given-names>G.</given-names></name>
</person-group><article-title>Molecular Mechanisms of Proteinuria in Minimal Change Disease</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>761600</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.761600</pub-id><pub-id pub-id-type="pmid">35004732</pub-id>
</element-citation></ref><ref id="B6-pathophysiology-32-00019"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>K.</given-names></name>
<name><surname>Ishibe</surname><given-names>S.</given-names></name>
</person-group><article-title>Podocyte endocytosis in the regulation of the glomerular filtration barrier</article-title><source>Am. J. Physiol. Ren. Physiol.</source><year>2015</year><volume>309</volume><fpage>F398</fpage><lpage>F405</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00136.2015</pub-id><pub-id pub-id-type="pmid">26084928</pub-id>
</element-citation></ref><ref id="B7-pathophysiology-32-00019"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vega-Warner</surname><given-names>V.</given-names></name>
<name><surname>Ransom</surname><given-names>R.F.</given-names></name>
<name><surname>Vincent</surname><given-names>A.M.</given-names></name>
<name><surname>Brosius</surname><given-names>F.C.</given-names></name>
<name><surname>Smoyer</surname><given-names>W.E.</given-names></name>
</person-group><article-title>Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside</article-title><source>Kidney Int.</source><year>2004</year><volume>66</volume><fpage>1881</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00962.x</pub-id><pub-id pub-id-type="pmid">15496159</pub-id>
</element-citation></ref><ref id="B8-pathophysiology-32-00019"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamireddy</surname><given-names>R.</given-names></name>
<name><surname>Kavuri</surname><given-names>S.</given-names></name>
<name><surname>Devi</surname><given-names>S.</given-names></name>
<name><surname>Vemula</surname><given-names>H.</given-names></name>
<name><surname>Chandana</surname><given-names>D.</given-names></name>
<name><surname>Harinarayanan</surname><given-names>S.</given-names></name>
<name><surname>James</surname><given-names>R.</given-names></name>
<name><surname>Rao</surname><given-names>A.</given-names></name>
</person-group><article-title>Oxidative stress in pediatric nephrotic syndrome</article-title><source>Clin. Chim. Acta</source><year>2002</year><volume>325</volume><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0009-8981(02)00294-2</pub-id><pub-id pub-id-type="pmid">12367779</pub-id>
</element-citation></ref><ref id="B9-pathophysiology-32-00019"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruno</surname><given-names>V.</given-names></name>
<name><surname>M&#x000fc;hlig</surname><given-names>A.K.</given-names></name>
<name><surname>Oh</surname><given-names>J.</given-names></name>
<name><surname>Licht</surname><given-names>C.</given-names></name>
</person-group><article-title>New insights into the immune functions of podocytes: The role of complement</article-title><source>Mol. Cell. Pediatr.</source><year>2023</year><volume>10</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s40348-023-00157-3</pub-id><pub-id pub-id-type="pmid">37059832</pub-id>
</element-citation></ref><ref id="B10-pathophysiology-32-00019"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>C.B.</given-names></name>
<name><surname>Pippin</surname><given-names>J.W.</given-names></name>
<name><surname>Krofft</surname><given-names>R.D.</given-names></name>
<name><surname>Shankland</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo</article-title><source>Kidney Int.</source><year>2006</year><volume>70</volume><fpage>1962</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5001965</pub-id><pub-id pub-id-type="pmid">17035936</pub-id>
</element-citation></ref><ref id="B11-pathophysiology-32-00019"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sim&#x000f5;es</surname><given-names>E.S.A.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>E.A.</given-names></name>
<name><surname>Cheung</surname><given-names>W.W.</given-names></name>
<name><surname>Mak</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Redox Signaling in Chronic Kidney Disease-Associated Cachexia</article-title><source>Antioxid</source><year>2023</year><volume>12</volume><elocation-id>945</elocation-id><pub-id pub-id-type="doi">10.3390/antiox12040945</pub-id><pub-id pub-id-type="pmid">37107320</pub-id>
</element-citation></ref><ref id="B12-pathophysiology-32-00019"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yaribeygi</surname><given-names>H.</given-names></name>
<name><surname>Farrokhi</surname><given-names>F.R.</given-names></name>
<name><surname>Rezaee</surname><given-names>R.</given-names></name>
<name><surname>Sahebkar</surname><given-names>A.</given-names></name>
</person-group><article-title>Oxidative stress induces renal failure: A review of possible molecular pathways</article-title><source>J. Cell. Biochem.</source><year>2018</year><volume>119</volume><fpage>2990</fpage><lpage>2998</lpage><pub-id pub-id-type="doi">10.1002/jcb.26450</pub-id><pub-id pub-id-type="pmid">29111576</pub-id>
</element-citation></ref><ref id="B13-pathophysiology-32-00019"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beaman</surname><given-names>M.</given-names></name>
<name><surname>Birtwistle</surname><given-names>R.</given-names></name>
<name><surname>Howie</surname><given-names>A.J.</given-names></name>
<name><surname>Michael</surname><given-names>J.</given-names></name>
<name><surname>Adu</surname><given-names>D.</given-names></name>
</person-group><article-title>The role of superoxide anion and hydrogen peroxide in glomerular injury induced by puromycin aminonucleoside in rats</article-title><source>Clin. Sci.</source><year>1987</year><volume>73</volume><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1042/cs0730329</pub-id></element-citation></ref><ref id="B14-pathophysiology-32-00019"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ornellas</surname><given-names>F.M.</given-names></name>
<name><surname>Ramalho</surname><given-names>R.J.</given-names></name>
<name><surname>Fanelli</surname><given-names>C.</given-names></name>
<name><surname>Garnica</surname><given-names>M.R.</given-names></name>
<name><surname>Malheiros</surname><given-names>D.</given-names></name>
<name><surname>Martini</surname><given-names>S.V.</given-names></name>
<name><surname>Morales</surname><given-names>M.M.</given-names></name>
<name><surname>Noronha</surname><given-names>I.L.</given-names></name>
</person-group><article-title>Mesenchymal Stromal Cells Induce Podocyte Protection in the Puromycin Injury Model</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>19604</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-55284-7</pub-id><pub-id pub-id-type="pmid">31862892</pub-id>
</element-citation></ref><ref id="B15-pathophysiology-32-00019"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srivastava</surname><given-names>T.</given-names></name>
<name><surname>Sharma</surname><given-names>M.</given-names></name>
<name><surname>Yew</surname><given-names>K.H.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Duncan</surname><given-names>R.S.</given-names></name>
<name><surname>Saleem</surname><given-names>M.A.</given-names></name>
<name><surname>McCarthy</surname><given-names>E.T.</given-names></name>
<name><surname>Kats</surname><given-names>A.</given-names></name>
<name><surname>Cudmore</surname><given-names>P.A.</given-names></name>
<name><surname>Alon</surname><given-names>U.S.</given-names></name>
<etal/>
</person-group><article-title>LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: Changes in TLR profile</article-title><source>J. Cell Commun. Signal.</source><year>2013</year><volume>7</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s12079-012-0184-0</pub-id><pub-id pub-id-type="pmid">23161414</pub-id>
</element-citation></ref><ref id="B16-pathophysiology-32-00019"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujii</surname><given-names>Y.</given-names></name>
<name><surname>Matsumura</surname><given-names>H.</given-names></name>
<name><surname>Yamazaki</surname><given-names>S.</given-names></name>
<name><surname>Shirasu</surname><given-names>A.</given-names></name>
<name><surname>Nakakura</surname><given-names>H.</given-names></name>
<name><surname>Ogihara</surname><given-names>T.</given-names></name>
<name><surname>Ashida</surname><given-names>A.</given-names></name>
</person-group><article-title>Efficacy of a mitochondrion-targeting agent for reducing the level of urinary protein in rats with puromycin aminonucleoside-induced minimal-change nephrotic syndrome</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0227414</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0227414</pub-id><pub-id pub-id-type="pmid">31905213</pub-id>
</element-citation></ref><ref id="B17-pathophysiology-32-00019"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terada</surname><given-names>K.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Nagahama</surname><given-names>H.</given-names></name>
<name><surname>Kataoka-Sasaki</surname><given-names>Y.</given-names></name>
<name><surname>Oka</surname><given-names>S.</given-names></name>
<name><surname>Ukai</surname><given-names>R.</given-names></name>
<name><surname>Yokoyama</surname><given-names>T.</given-names></name>
<name><surname>Iizuka</surname><given-names>Y.</given-names></name>
<name><surname>Sakai</surname><given-names>T.</given-names></name>
<name><surname>Fukumura</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic efficacy of intravenous infusion of mesenchymal stem cells in rat perinatal brain injury</article-title><source>Pediatr. Res.</source><year>2023</year><volume>94</volume><fpage>1921</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1038/s41390-023-02717-9</pub-id><pub-id pub-id-type="pmid">37422495</pub-id>
</element-citation></ref><ref id="B18-pathophysiology-32-00019"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Honmou</surname><given-names>O.</given-names></name>
<name><surname>Kato</surname><given-names>K.</given-names></name>
<name><surname>Nonaka</surname><given-names>T.</given-names></name>
<name><surname>Houkin</surname><given-names>K.</given-names></name>
<name><surname>Hamada</surname><given-names>H.</given-names></name>
<name><surname>Kocsis</surname><given-names>J.</given-names></name>
</person-group><article-title>Neural differentiation potential of peripheral blood- and bone-marrow-derived precursor cells</article-title><source>Brain Res.</source><year>2006</year><volume>1123</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.09.044</pub-id><pub-id pub-id-type="pmid">17064670</pub-id>
</element-citation></ref><ref id="B19-pathophysiology-32-00019"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takemura</surname><given-names>M.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Kataoka-Sasaki</surname><given-names>Y.</given-names></name>
<name><surname>Kiyose</surname><given-names>R.</given-names></name>
<name><surname>Nagahama</surname><given-names>H.</given-names></name>
<name><surname>Oka</surname><given-names>S.</given-names></name>
<name><surname>Ukai</surname><given-names>R.</given-names></name>
<name><surname>Yokoyama</surname><given-names>T.</given-names></name>
<name><surname>Kocsis</surname><given-names>J.D.</given-names></name>
<name><surname>Ueba</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Repeated intravenous infusion of mesenchymal stem cells for enhanced functional recovery in a rat model of chronic cerebral ischemia</article-title><source>J. Neurosurg.</source><year>2021</year><volume>137</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3171/2021.8.JNS21687</pub-id><pub-id pub-id-type="pmid">34798608</pub-id>
</element-citation></ref><ref id="B20-pathophysiology-32-00019"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frenk</surname><given-names>S.</given-names></name>
<name><surname>Antonowicz</surname><given-names>I.</given-names></name>
<name><surname>Craig</surname><given-names>J.M.</given-names></name>
<name><surname>Metcoff</surname><given-names>J.</given-names></name>
</person-group><article-title>Experimental nephrotic syndrome induced in rats by aminonucleoside; renal lesions and body electrolyte composition</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1955</year><volume>89</volume><fpage>424</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.3181/00379727-89-21833</pub-id><pub-id pub-id-type="pmid">13254783</pub-id>
</element-citation></ref><ref id="B21-pathophysiology-32-00019"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosoyamada</surname><given-names>M.</given-names></name>
<name><surname>Yan</surname><given-names>K.</given-names></name>
<name><surname>Nishibori</surname><given-names>Y.</given-names></name>
<name><surname>Takiue</surname><given-names>Y.</given-names></name>
<name><surname>Kudo</surname><given-names>A.</given-names></name>
<name><surname>Kawakami</surname><given-names>H.</given-names></name>
<name><surname>Shibasaki</surname><given-names>T.</given-names></name>
<name><surname>Endou</surname><given-names>H.</given-names></name>
</person-group><article-title>Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis</article-title><source>J. Pharmacol. Sci.</source><year>2005</year><volume>97</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1254/jphs.FP0040802</pub-id><pub-id pub-id-type="pmid">15684566</pub-id>
</element-citation></ref><ref id="B22-pathophysiology-32-00019"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Deng</surname><given-names>Y.</given-names></name>
</person-group><article-title>Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e85690</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085690</pub-id><pub-id pub-id-type="pmid">24454919</pub-id>
</element-citation></ref><ref id="B23-pathophysiology-32-00019"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harada</surname><given-names>T.</given-names></name>
<name><surname>Shimomura</surname><given-names>Y.</given-names></name>
<name><surname>Nishida</surname><given-names>O.</given-names></name>
<name><surname>Maeda</surname><given-names>M.</given-names></name>
<name><surname>Kato</surname><given-names>Y.</given-names></name>
<name><surname>Nakamura</surname><given-names>T.</given-names></name>
<name><surname>Kuriyama</surname><given-names>N.</given-names></name>
<name><surname>Komura</surname><given-names>H.</given-names></name>
</person-group><article-title>Effects of recombinant human soluble thrombomodulin on neutrophil extracellular traps in the kidney of a mouse model of endotoxin shock</article-title><source>Fujita Med. J.</source><year>2023</year><volume>9</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.20407/fmj.2022-026</pub-id><pub-id pub-id-type="pmid">37554943</pub-id>
</element-citation></ref><ref id="B24-pathophysiology-32-00019"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.K.</given-names></name>
<name><surname>Kwon</surname><given-names>T.</given-names></name>
<name><surname>Kim</surname><given-names>D.J.</given-names></name>
<name><surname>Huh</surname><given-names>W.</given-names></name>
<name><surname>Kim</surname><given-names>Y.G.</given-names></name>
<name><surname>Oh</surname><given-names>H.Y.</given-names></name>
<name><surname>Kawachi</surname><given-names>H.</given-names></name>
</person-group><article-title>Ultrastructural study on nephrin expression in experimental puromycin aminonucleoside nephrosis</article-title><source>Nephrol. Dial. Transpl.</source><year>2004</year><volume>19</volume><fpage>2981</fpage><lpage>2986</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfh489</pub-id></element-citation></ref><ref id="B25-pathophysiology-32-00019"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabata</surname><given-names>H.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Kataoka-Sasaki</surname><given-names>Y.</given-names></name>
<name><surname>Shinkai</surname><given-names>N.</given-names></name>
<name><surname>Ichihara</surname><given-names>K.</given-names></name>
<name><surname>Masumori</surname><given-names>N.</given-names></name>
<name><surname>Kocsis</surname><given-names>J.D.</given-names></name>
<name><surname>Honmou</surname><given-names>O.</given-names></name>
</person-group><article-title>Possible role of intravenous administration of mesenchymal stem cells to alleviate interstitial cystitis/bladder pain syndrome in a Toll-like receptor-7 agonist-induced experimental animal model in rat</article-title><source>BMC Urol.</source><year>2021</year><volume>21</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.1186/s12894-021-00923-3</pub-id><pub-id pub-id-type="pmid">34774029</pub-id>
</element-citation></ref><ref id="B26-pathophysiology-32-00019"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y.</given-names></name>
<name><surname>Wharram</surname><given-names>B.L.</given-names></name>
<name><surname>Lee</surname><given-names>S.K.</given-names></name>
<name><surname>Wickman</surname><given-names>L.</given-names></name>
<name><surname>Goyal</surname><given-names>M.</given-names></name>
<name><surname>Venkatareddy</surname><given-names>M.</given-names></name>
<name><surname>Chang</surname><given-names>J.W.</given-names></name>
<name><surname>Wiggins</surname><given-names>J.E.</given-names></name>
<name><surname>Lienczewski</surname><given-names>C.</given-names></name>
<name><surname>Kretzler</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Urine podocyte mRNAs mark progression of renal disease</article-title><source>J. Am. Soc. Nephrol.</source><year>2009</year><volume>20</volume><fpage>1041</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007121328</pub-id><pub-id pub-id-type="pmid">19389856</pub-id>
</element-citation></ref><ref id="B27-pathophysiology-32-00019"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima-Posada</surname><given-names>I.</given-names></name>
<name><surname>Fontana</surname><given-names>F.</given-names></name>
<name><surname>P&#x000e9;rez-Villalva</surname><given-names>R.</given-names></name>
<name><surname>Berman-Parks</surname><given-names>N.</given-names></name>
<name><surname>Bobadilla</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Pirfenidone prevents acute kidney injury in the rat</article-title><source>BMC Nephrol.</source><year>2019</year><volume>20</volume><elocation-id>158</elocation-id><pub-id pub-id-type="doi">10.1186/s12882-019-1364-4</pub-id><pub-id pub-id-type="pmid">31068174</pub-id>
</element-citation></ref><ref id="B28-pathophysiology-32-00019"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmittgen</surname><given-names>T.D.</given-names></name>
<name><surname>Livak</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Analyzing real-time PCR data by the comparative C(T) method</article-title><source>Nat. Protoc.</source><year>2008</year><volume>3</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id><pub-id pub-id-type="pmid">18546601</pub-id>
</element-citation></ref><ref id="B29-pathophysiology-32-00019"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basgen</surname><given-names>J.M.</given-names></name>
<name><surname>Wong</surname><given-names>J.S.</given-names></name>
<name><surname>Ray</surname><given-names>J.</given-names></name>
<name><surname>Nicholas</surname><given-names>S.B.</given-names></name>
<name><surname>Campbell</surname><given-names>K.N.</given-names></name>
</person-group><article-title>Podocyte Foot Process Effacement Precedes Albuminuria and Glomerular Hypertrophy in CD2-Associated Protein Deficient Mice</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>745319</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.745319</pub-id></element-citation></ref><ref id="B30-pathophysiology-32-00019"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lannigan</surname><given-names>R.</given-names></name>
<name><surname>Kark</surname><given-names>R.</given-names></name>
<name><surname>Pollak</surname><given-names>V.E.</given-names></name>
</person-group><article-title>The effect of a single intravenous injection of aminonucleoside of puromycin on the rat kidney: A light- and electron-microscope study</article-title><source>J. Pathol. Bacteriol.</source><year>1962</year><volume>83</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1002/path.1700830204</pub-id><pub-id pub-id-type="pmid">14462208</pub-id>
</element-citation></ref><ref id="B31-pathophysiology-32-00019"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gwinner</surname><given-names>W.</given-names></name>
<name><surname>Landmesser</surname><given-names>U.</given-names></name>
<name><surname>Brandes</surname><given-names>R.P.</given-names></name>
<name><surname>Kubat</surname><given-names>B.</given-names></name>
<name><surname>Plasger</surname><given-names>J.</given-names></name>
<name><surname>Eberhard</surname><given-names>O.</given-names></name>
<name><surname>Koch</surname><given-names>K.M.</given-names></name>
<name><surname>Olbricht</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy</article-title><source>J. Am. Soc. Nephrol.</source><year>1997</year><volume>8</volume><fpage>1722</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1681/ASN.V8111722</pub-id><pub-id pub-id-type="pmid">9355075</pub-id>
</element-citation></ref><ref id="B32-pathophysiology-32-00019"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.C.</given-names></name>
<name><surname>Guh</surname><given-names>J.Y.</given-names></name>
<name><surname>Lai</surname><given-names>Y.H.</given-names></name>
</person-group><article-title>Alterations of glomerular and extracellular glutathione peroxidase levels in patients and rats with focal segmental glomerulosclerosis</article-title><source>J. Lab. Clin. Med.</source><year>2001</year><volume>137</volume><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1067/mlc.2001.113231</pub-id><pub-id pub-id-type="pmid">11283522</pub-id>
</element-citation></ref><ref id="B33-pathophysiology-32-00019"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>Y.A.</given-names></name>
<name><surname>Park</surname><given-names>C.W.</given-names></name>
</person-group><article-title>Catalytic Antioxidants in the Kidney</article-title><source>Antioxid</source><year>2021</year><volume>10</volume><elocation-id>130</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10010130</pub-id><pub-id pub-id-type="pmid">33477607</pub-id>
</element-citation></ref><ref id="B34-pathophysiology-32-00019"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diamond</surname><given-names>J.R.</given-names></name>
<name><surname>Bonventre</surname><given-names>J.V.</given-names></name>
<name><surname>Karnovsky</surname><given-names>M.J.</given-names></name>
</person-group><article-title>A role for oxygen free radicals in aminonucleoside nephrosis</article-title><source>Kidney Int.</source><year>1986</year><volume>29</volume><fpage>478</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/ki.1986.24</pub-id><pub-id pub-id-type="pmid">3702206</pub-id>
</element-citation></ref><ref id="B35-pathophysiology-32-00019"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamanaka</surname><given-names>M.</given-names></name>
<name><surname>Tamura</surname><given-names>Y.</given-names></name>
<name><surname>Kuribayashi-Okuma</surname><given-names>E.</given-names></name>
<name><surname>Uchida</surname><given-names>S.</given-names></name>
<name><surname>Shibata</surname><given-names>S.</given-names></name>
</person-group><article-title>Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats</article-title><source>Am. J. Physiol. Ren. Physiol.</source><year>2023</year><volume>324</volume><fpage>F168</fpage><lpage>F178</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00144.2022</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pathophysiology-32-00019-f001"><label>Figure 1</label><caption><p><bold>Experimental protocol.</bold> PAN or NS was injected subcutaneously on day 0. On day 5, PAN-injected rats received an intravenous infusion of vehicle or MSCs on day 7. Urine was collected before PAN or NS injection, and on days 5, 10, and 15 after PAN or NS injection. Blood and tissue were collected for histological analyses, and RT-PCR analyses were conducted on day 15. Tissue for detection of GFP was collected on day 8. NS, normal saline; MSC, mesenchymal stem cell; PAN, puromycin aminonucleoside; qRT-PCR, quantitative reverse-transcription PCR.</p></caption><graphic xlink:href="pathophysiology-32-00019-g001" position="float"/></fig><fig position="float" id="pathophysiology-32-00019-f002"><label>Figure 2</label><caption><p><bold>Urine and blood analysis.</bold> (<bold>a</bold>) Urine albumin was measured before PAN or NS injection and on days 5, 10, and 15 after PAN or NS injection. MSC vs. Vehicle: * <italic toggle="yes">p</italic> &#x0003c; 0.05, Intact vs. Vehicle &#x02021; <italic toggle="yes">p</italic> &#x0003c; 0.01, Intact vs. MSC <sup>&#x000a7;&#x000a7;</sup>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.01. (<bold>b</bold>) Serum albumin (sAlb), (<bold>c</bold>) serum creatinine (sCr). sAlb and sCr were measured on day 15. ** <italic toggle="yes">p</italic>&#x02009; &#x0003c; &#x02009;0.01, n = 6 for each group. Error bars indicate SEM. Closed marks (&#x025a0;, &#x025cf;, &#x025b2;) indicate average values, and open marks (&#x025a1;, &#x025ef;, &#x025b3;) indicate individual values.</p></caption><graphic xlink:href="pathophysiology-32-00019-g002" position="float"/></fig><fig position="float" id="pathophysiology-32-00019-f003"><label>Figure 3</label><caption><p><bold>Light microscopic analysis with PAS staining.</bold> (<bold>a</bold>) Intact, (<bold>b</bold>) PAN-Vehicle, and (<bold>c</bold>) PAN-MSC groups. Scale bar = 50 &#x003bc;m. MSC, mesenchymal stem cell; PAN, puromycin aminonucleoside.</p></caption><graphic xlink:href="pathophysiology-32-00019-g003" position="float"/></fig><fig position="float" id="pathophysiology-32-00019-f004"><label>Figure 4</label><caption><p><bold>Electron microscopic analysis.</bold> Representative electron microscopy images of (<bold>a</bold>) Intact, (<bold>b</bold>) PAN-Vehicle, and (<bold>c</bold>) PAN-MSC groups. (<bold>d</bold>) Quantification of podocyte foot width. Scale bar = 1 &#x003bc;m. ** <italic toggle="yes">p</italic>&#x02009; &#x0003c; &#x02009;0.01, n = 6 for each group. Error bars indicate SEM. Open marks (&#x02610;, &#x025ef;, &#x025b3;) indicate individual values.</p></caption><graphic xlink:href="pathophysiology-32-00019-g004" position="float"/></fig><fig position="float" id="pathophysiology-32-00019-f005"><label>Figure 5</label><caption><p><bold>Gene expression of podocyte-associated and oxidative stress-related genes.</bold> Relative mRNA expression levels of (<bold>a</bold>) <italic toggle="yes">NPHS1</italic>, (<bold>b</bold>) <italic toggle="yes">NPHS2</italic>, (<bold>c</bold>) <italic toggle="yes">PODXL</italic>, (<bold>d</bold>) <italic toggle="yes">SOD1</italic>, (<bold>e</bold>) <italic toggle="yes">SOD2</italic>, and (<bold>f</bold>) <italic toggle="yes">GPX1</italic>. * <italic toggle="yes">p</italic>&#x02009; &#x0003c; &#x02009;0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, n = 6 for each group. Error bars indicate SEM. Open marks (&#x02610;, &#x025ef;, &#x025b3;) indicate individual values.</p></caption><graphic xlink:href="pathophysiology-32-00019-g005" position="float"/></fig><fig position="float" id="pathophysiology-32-00019-f006"><label>Figure 6</label><caption><p><bold>Distribution of GFP-MSCs in vivo.</bold> The intravenously infused GFP-MSCs (green) were observed in the DAPI (blue)-counterstained glomerulus (<bold>a</bold>) 1 day after GFP-MSC administration. (<bold>b</bold>) No GFP-positive signals in the non-GFP-MSC (WT-MSC)-infused MCD rats. Scale bar = 300 &#x003bc;m (<bold>a</bold>,<bold>b</bold>) and 100 &#x003bc;m (inset in a). DAPI, diamidino-2-phenylindole; GFP, green fluorescent protein; MCD, minimal change disease; MSC, mesenchymal stem cell; WT, wild type.</p></caption><graphic xlink:href="pathophysiology-32-00019-g006" position="float"/></fig></floats-group></article>